Stock Analysis
Pfizer Inc. (PFE) Stock Analysis
Pfizer Inc. (PFE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Pfizer Inc. (PFE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Quality is the weakest current factor at 54/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PFE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $29.85 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $162.72B |
| P/E Ratio (TTM) | 37.72 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-28) | -$0.04 |
| Revenue (quarter ended 2026-06-28) | $15.03B |
| Dividend Yield (TTM) | 6.02% |
| Beta | 0.28 |
| Volume | 22.2M |
| 52-week range | $23.62-$30.25 |
| RSI 14 | 69.79 |
| 50-Day SMA | $28.15 |
| 200-Day SMA | $26.64 |
| Analyst Price Target | $29.00 |
| Next Earnings | Nov 3, 2026 |
PFEPfizer Inc.
Healthcare / Drug Manufacturers - General
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum79
- Value67
- Quality54
- Risk resilience54
- Sentiment—
PFE Stock Analysis Summary
Pfizer Inc. (PFE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Quality is the weakest current factor at 54/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, PFE has AIQ Score of 64/100 with Momentum base of 79/100 and fading Quality at 54/100. Wait for component alignment before adding exposure.
Momentum (79/100) leads while Quality (54/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.86% stock move · PFE classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PFE Bullish or Bearish Right Now?
PFE currently has a neutral overall setup. Momentum is the strongest factor at 79/100, while Quality is weakest at 54/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 79/100.
- - Price is +6.05% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (37 vs 6).
- - Analyst target implies -2.85% downside from the latest quote.
Current Consensus
PFE's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 2 neutral, and 6 sell votes. PFE's 14-day RSI is 69.79, which places the stock in a constructive momentum range. PFE's beta is 0.28, indicating lower market sensitivity than the broad market.
What Changed in PFE?
The largest recent change in PFE is Momentum moving up by 8.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the PFE Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PFE Decision Framework
Public evidence layers, setup checks, and risk context for Pfizer Inc..
Pfizer Inc. (PFE) Stock Analysis
Pfizer Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 79/100. Beta is 0.28, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PFE is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 79/100 while quality lags at 54/100. |
| Factor Evidence | Momentum 79/100 · Value 67/100 · Quality 54/100 · Risk 54/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 79/100.
Momentum is 79/100 and RSI (14) is 69.8.
PFE is in a Neutral regime at 64/100.
Risk factor is 54/100 with beta 0.28 and annual volatility 21.51%.
Current conflict: momentum leads at 79/100 while quality lags at 54/100.
PFE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PFE Fundamentals
PFE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PFE Technical Analysis
PFE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PFE Stock Catalysts
Track PFE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PFE Dividend Analysis
PFE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PFE Financial Data
PFE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PFE Risk Analysis
PFE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PFE Stock News
PFE stock news, market tone, recent headlines, and catalyst context.
PFE vs Large-Cap Pharma Peers
Current peer cohort: PFE · MRK · JNJ · ABBV · LLY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PFE Current stock | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | Current |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | PFE vs MRK |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | PFE vs JNJ |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | PFE vs ABBV |
| LLY Eli Lilly | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | PFE vs LLY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular PFE Comparisons
How PFE scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 28, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PFE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PFE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PFE Stock FAQ
What is PFE stock price today?
Pfizer Inc.'s current stock price is $29.85. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PFE bullish or bearish right now?
PFE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PFE's market cap?
PFE's market cap is $162.72B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PFE's current P/E ratio?
PFE's current P/E ratio is 37.72 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PFE's RSI?
PFE's 14-day RSI is 69.79 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PFE above its 50-day and 200-day moving averages?
PFE is 6.05% from its 50-day SMA and 12.07% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PFE's next earnings date?
PFE's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PFE pay a dividend?
PFE's dividend yield is 6.02% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.